AXSOME THERAPEUTICS, INC. Operating Expenses
AXSOME THERAPEUTICS, INC. (AXSM) reported Operating Expenses of $38.29 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2022-05-02
- AXSOME THERAPEUTICS, INC. operating expenses for the quarter ending 2022-03-31 was $38.29M, a 37.51% increase year-over-year.
- AXSOME THERAPEUTICS, INC. operating expenses for the quarter ending 2021-12-31 was $32.61M, a 17.53% increase year-over-year.
- AXSOME THERAPEUTICS, INC. operating expenses for the quarter ending 2021-09-30 was $33.41M, a 58.13% increase year-over-year.
- AXSOME THERAPEUTICS, INC. operating expenses for the quarter ending 2021-06-30 was $30.85M, a 73.51% increase year-over-year.
- AXSOME THERAPEUTICS, INC. operating expenses for fiscal 2021 was $124.71M, a 25.79% increase from fiscal 2020.
- AXSOME THERAPEUTICS, INC. operating expenses for fiscal 2020 was $99.14M, a 47.43% increase from fiscal 2019.
- AXSOME THERAPEUTICS, INC. operating expenses for fiscal 2019 was $67.25M, a 104.72% increase from fiscal 2018.
- AXSOME THERAPEUTICS, INC. operating expenses for fiscal 2018 was $32.85M, a 20.92% increase from fiscal 2017.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2022-03-31 | $38.29M 10-Q · filed 2022-05-02 | $70.90M derived: sum of 2 quarters · filed 2022-05-02 | $104.30M derived: sum of 3 quarters · filed 2022-05-02 | $135.15M derived: sum of 4 quarters · filed 2022-05-02 |
| 2021-12-31 | $32.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $66.02M derived: sum of 2 quarters · filed 2022-03-01 | $96.86M derived: sum of 3 quarters · filed 2022-03-01 | $124.71M 10-K · filed 2022-03-01 |
| 2021-09-30 | $33.41M 10-Q · filed 2021-11-08 | $64.25M derived: sum of 2 quarters · filed 2021-11-08 | $92.10M 10-Q · filed 2021-11-08 | $119.84M derived: sum of 4 quarters · filed 2022-05-02 |
| 2021-06-30 | $30.85M 10-Q · filed 2021-08-09 | $58.69M 10-Q · filed 2021-08-09 | $86.44M derived: sum of 3 quarters · filed 2022-05-02 | $107.56M derived: sum of 4 quarters · filed 2022-05-02 |
| 2021-03-31 | $27.84M 10-Q · filed 2022-05-02 | $55.59M derived: sum of 2 quarters · filed 2022-05-02 | $76.72M derived: sum of 3 quarters · filed 2022-05-02 | $94.49M derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | $27.74M 10-K · filed 2021-03-01 | $48.87M derived: sum of 2 quarters · filed 2021-11-08 | $66.65M derived: sum of 3 quarters · filed 2021-11-08 | $99.14M 10-K · filed 2022-03-01 |
| 2020-09-30 | $21.13M 10-Q · filed 2021-11-08 | $38.91M derived: sum of 2 quarters · filed 2021-11-08 | $71.40M 10-Q · filed 2021-11-08 | $95.83M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $17.78M 10-Q · filed 2021-08-09 | $50.27M 10-Q · filed 2021-08-09 | $74.70M derived: sum of 3 quarters · filed 2021-08-09 | $93.65M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $32.49M 10-Q · filed 2021-05-10 | $56.92M derived: sum of 2 quarters · filed 2021-05-10 | $75.87M derived: sum of 3 quarters · filed 2021-05-10 | $89.32M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $24.43M 10-K · filed 2021-03-01 | $43.38M derived: sum of 2 quarters · filed 2021-03-01 | $56.82M derived: sum of 3 quarters · filed 2021-03-01 | $67.25M 10-K · filed 2022-03-01 |
| 2019-09-30 | $18.95M 10-K · filed 2021-03-01 | $32.40M derived: sum of 2 quarters · filed 2021-03-01 | $42.82M 10-Q · filed 2020-11-05 | $52.27M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $13.45M 10-K · filed 2021-03-01 | $23.87M 10-Q · filed 2020-08-10 | $33.32M derived: sum of 3 quarters · filed 2021-03-01 | $41.56M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $10.42M 10-K · filed 2021-03-01 | $19.87M derived: sum of 2 quarters · filed 2021-03-01 | $28.12M derived: sum of 3 quarters · filed 2021-03-01 | $36.10M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $9.45M 10-K · filed 2020-03-12 | $17.69M derived: sum of 2 quarters · filed 2020-03-12 | $25.68M derived: sum of 3 quarters · filed 2020-03-12 | $32.85M 10-K · filed 2021-03-01 |
| 2018-09-30 | $8.24M 10-K · filed 2020-03-12 | $16.23M derived: sum of 2 quarters · filed 2020-03-12 | $23.40M 10-Q · filed 2019-11-07 | $29.84M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $7.99M 10-K · filed 2020-03-12 | $15.15M 10-Q · filed 2019-08-08 | $21.60M derived: sum of 3 quarters · filed 2020-03-12 | $27.89M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $7.16M 10-K · filed 2020-03-12 | $13.61M derived: sum of 2 quarters · filed 2020-03-12 | $19.90M derived: sum of 3 quarters · filed 2020-03-12 | $26.66M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $6.44M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $12.74M derived: sum of 2 quarters · filed 2020-03-12 | $19.49M derived: sum of 3 quarters · filed 2020-03-12 | $27.16M 10-K · filed 2020-03-12 |
| 2017-09-30 | $6.30M 10-Q · filed 2018-11-09 | $13.05M derived: sum of 2 quarters · filed 2018-11-09 | $20.72M 10-Q · filed 2018-11-09 | $28.35M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $6.75M 10-Q · filed 2018-08-08 | $14.42M 10-Q · filed 2018-08-08 | $22.05M derived: sum of 3 quarters · filed 2019-03-15 | $29.26M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $7.67M 10-Q · filed 2018-05-08 | $15.30M derived: sum of 2 quarters · filed 2019-03-15 | $22.51M derived: sum of 3 quarters · filed 2019-03-15 | $29.33M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $7.63M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $14.83M derived: sum of 2 quarters · filed 2019-03-15 | $21.66M derived: sum of 3 quarters · filed 2019-03-15 | $27.54M 10-K · filed 2019-03-15 |
| 2016-09-30 | $7.21M 10-Q · filed 2017-11-08 | $14.04M derived: sum of 2 quarters · filed 2017-11-08 | $19.92M 10-Q · filed 2017-11-08 | $23.07M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | $6.83M 10-Q · filed 2017-08-09 | $12.71M 10-Q · filed 2017-08-09 | $15.86M derived: sum of 3 quarters · filed 2018-03-07 | $17.89M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $5.88M 10-Q · filed 2017-05-09 | $9.04M derived: sum of 2 quarters · filed 2018-03-07 | $11.06M derived: sum of 3 quarters · filed 2018-03-07 | $13.15M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $5.18M derived: sum of 2 quarters · filed 2018-03-07 | $7.26M derived: sum of 3 quarters · filed 2018-03-07 | $9.20M 10-K · filed 2018-03-07 |
| 2015-09-30 | $2.02M 10-Q · filed 2016-11-14 | $4.11M derived: sum of 2 quarters · filed 2016-11-14 | $6.04M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $2.08M 10-Q · filed 2016-08-09 | $4.02M 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $1.93M 10-Q/A · filed 2016-08-09 | |||
| 2014-12-31 | $5.67M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |